Regeneron Pharmaceuticals has expanded its ophthalmology portfolio, acquiring exclusive rights to two antibodies invented at Regeneron and previously part of its collaboration with Sanofi. The antibodies target the PDGF (platelet derived growth factor) family of receptors and ligands in ophthalmology and all other indications. Antibodies to PDGF and ANG2 are currently in preclinical development for use in ophthalmology.
Regeneron will pay Sanofi $10 million upfront, as much as $40 million in development milestones, and royalties on sales. With respect to ANG2 antibodies in ophthalmology, Regeneron will pay Sanofi $10 million upfront, a potential $5 million development milestones, and royalties on sales.
Regeneron and Sanofi will continue to develop Antibodies to ANG2 outside of ophthalmology under their antibody collaboration agreement, including REGN910 (SAR 307746), which is currently in Phase I development in patients with advanced malignancies.
Regeneron Acquires Sanofi Ophthalmology Programs
Published May 3, 2013
blog comments powered by Disqus